The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
VelasquezW., SwanF., RedmanJ.Combination of etoposide, high-dose ARA-C and SoluMedrol with or without Platinol in relapsing or resistant lymphoma. Proc Am Soc Clin Onc.1989; 8: 256. [Abstract No. 999]
2.
VelasquezW.S., McLaughlinP., TuckerS.ESHAP an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol.1994; 12(6): 1169–76.
3.
AparicioJ., SeguraA., GarccráS., ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol.1999; 10: 593–5.
4.
WangW.S., ChiouT.J., LiuJ.H.ESHAP as salvage therapy for refractory Non-Hodgkin's lymphoma: Taiwan experience. Jpn J Clin Oncol.1999; 29(1): 33–7.
5.
WattsM.J., IngsS.J., LeverettD.ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m-2 and G-CSF for pretreated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer.2000; 82(2): 278–82.
6.
PetitJ., BoqueC., CancelasJ.A.Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilization regimen in resistant and relapsed lymphoma: A single-center study of 22 patients. Leuk Lymphoma.1999; 34(1-2): 119–27.
7.
RodriguezM.A., CabanillasF.C., VelasquezW.Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol.1995; 13(7): 1734–41.
8.
RomagueraJ.E., HagemeisterF.B., McLaughlinP.Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma.1998; 32(1-2): 97–106.
9.
CabanillasF., RodriguezM.A.MINE-ESHAP salvage therapy for recurrent and refractory lymphomas. Semin Hematol.1994; 31(2): 30.
10.
CaballeroM.D., AmigoM., HernándezJ.M.Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Ann Hematol.1997; 74: 79–82.
11.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–9.
12.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm.1999; 56: 729–64.
13.
NCCN antiemesis practice guidelines.The Complete Library of NCCN Oncology Practice Guidelines [CD- ROM]. Version 2000. Rockledge, PA: National Comprehensive Cancer Network; 2000.
14.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–94.
15.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–58.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18: 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34: 1857–64.
20.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors. Curr Opin Hematol.1999; 6: 145–51.
21.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care. Eur J Cancer.2000; 36: S15–S21.
22.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–9.
23.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–405.
24.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins;2001, 494–504.
25.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
26.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24: 969–90.
27.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins;2001: 483–93.
